Many people believe that using certain substances can lead to using more harmful ones later. This idea shows up often in conversations about addiction, especially when talking about alcohol, cigarettes, or cannabis.

These substances are commonly referred to as gateway drugs. The term suggests that trying them may increase the chances of moving on to other drugs over time. In this blog, we’ll look at what “gateway drugs” really means, clear up common myths, and explore what research actually says.

What Are Gateway Drugs?

Gateway drugs are substances that some people believe can lead to the use of other, often more harmful, drugs over time. The idea is that trying one substance may increase the chances of trying others later.

Common examples include:

  • Alcohol
  • Nicotine (cigarettes, vaping, and chewing tobacco)
  • Cannabis
  • Bhaang (in certain cultural contexts)
  • Cough syrups (when misused)
  • Inhalants (like glue, Fevicol, petrol, or paint thinners)

Bhaang is a cannabis-based preparation that is sometimes consumed during festivals like Holi. Because it is culturally accepted in some settings, people may try it casually or at a younger age. Cough syrups, especially those containing codeine (an opioid), can be misused for their calming or euphoric effects. Since these medications are relatively easy to access, they can sometimes become an early point of exposure to substance use.

Inhalants such as glue (including Fevicol), petrol, or paint thinners are sometimes used because they are cheap and easily available. They can produce a quick high but are especially harmful. Chewing tobacco (like gutkha or khaini) is widely used and often introduced early, especially in certain social or regional contexts, making it another common first exposure to substance use.

These substances are often labeled as “gateways” because:

  • They are easy to access
  • They may feel socially acceptable or normalized
  • They are often a person’s first exposure to substance use

Where Did the Gateway Drug Theory Come From?

The idea of gateway drugs comes from early research on substance use, especially studies done in the mid-20th century. Researchers noticed a pattern: many people who used certain drugs had often started with substances like alcohol or nicotine.

This led to the idea of a “progression,” a step-by-step path where people move from so-called “softer” substances to stronger or more harmful ones over time. For example, someone might start with cigarettes or alcohol, then try cannabis, and later move on to other drugs.

Because this pattern seemed consistent in some groups, it became a widely accepted way of understanding substance use. Over time, this idea also shaped public policy and prevention programs. Many awareness campaigns began focusing on stopping early substance use, with the belief that it could prevent future drug use. It also influenced how schools, families, and communities talked about addiction, often using simple, cause-and-effect messaging.

However, while this model was useful in highlighting early risk, it did not fully explain why some people follow this path and others do not.

What Does Research Actually Say?

Research shows that there is a link between early use of substances (like alcohol or nicotine) and later use of other drugs. But this does not mean one directly causes the other. This is where the idea of correlation vs. causation becomes important. Just because two things are connected does not mean one leads to the other. For example, many people who use certain substances may go on to try others, but that doesn’t mean the first substance caused it.

Instead, research points to several underlying factors that influence substance use:

  • Genetics: Some people may be more vulnerable to addiction due to biological factors
  • Environment: Family dynamics, peer groups, and exposure all play a role
  • Mental health: Anxiety, depression, trauma, or stress can increase risk

These factors can make someone more likely to try multiple substances, regardless of where they start. Some studies do support the idea of a progression, showing patterns in how people report starting and continuing substance use. However, other research challenges this view, arguing that the pattern is not consistent for everyone and does not explain the root cause.

The Common Liability Model 

Researchers have proposed alternative explanations, such as the common liability model. This approach suggests that it’s not one drug leading to another, but rather shared risk factors that increase the likelihood of using different substances over time.

These shared risk factors can include:

  • Personality traits like impulsivity or sensation-seeking
  • Difficult life experiences, stress, or trauma
  • Mental health concerns
  • Social environment, such as peer influence or lack of support

This model helps explain why some people may try multiple substances, while others do not even if they are exposed to the same “gateway” drug.

Myths About Gateway Drugs

Myth 1: “Using a gateway drug guarantees addiction”

Trying a substance does not automatically lead to addiction. Many people do not develop problematic use.

Myth 2: “Everyone follows the same path”

Substance use does not follow a fixed sequence. People have different experiences and patterns.

Myth 3: “Stopping early use completely prevents later use”

Early prevention helps, but it does not fully remove the risk. Other factors still play a role.

Myth 4: “Certain drugs are inherently ‘safe’ or ‘unsafe’ in isolation”

No substance exists in a vacuum. Risk depends on how, why, and in what context it is used.

What This Means for Prevention and Treatment

Understanding substance use as complex and influenced by many factors changes how we approach prevention and treatment.

  • Build emotional regulation skills: Helping people understand and manage their emotions can reduce the need to rely on substances as a coping tool.
  • Strengthen coping mechanisms: Teaching healthier ways to deal with stress, anxiety, or difficult situations like problem-solving, relaxation, or seeking help can make a big difference.
  • Focus on support systems: Strong relationships with family, friends, or mentors provide stability and reduce isolation, which can lower risk.
  • Encourage early intervention: Addressing concerns early is important, but using fear or extreme warnings can backfire. Open, honest conversations are more effective.
  • Balance harm reduction and abstinence approaches: While some people aim for complete abstinence, others may benefit from harm reduction strategies that focus on reducing risks and improving safety. Both approaches can be valid, depending on the individual.

Conclusion

Substance use is not as simple as one drug leading to another. While the idea of gateway drugs highlights early exposure, it does not fully explain why people use substances or how patterns develop over time.

A more accurate understanding looks at the bigger picture: individual experiences, mental health, environment, and support systems. Not everyone follows the same path, and early use does not automatically lead to more harmful substance use. This also shapes how we talk about substances.

  • Focus on open, non-judgmental conversations instead of fear or shame
  • Avoid absolute statements like “this will lead to that”
  • Encourage awareness and informed choices, rather than control
  • Recognize that each person’s experience is different and influenced by many factors

When conversations are honest and supportive, people are more likely to seek help, reflect on their choices, and make safer decisions.

Sources

Kandel, D. B. (1975). Stages in adolescent involvement in drug use. Science, 190(4217), 912–914.

Kandel, D. B. (2002). Examining the gateway hypothesis: Stages and pathways of drug involvement. In D. B. Kandel (Ed.), Stages and pathways of drug involvement: 

Examining the gateway hypothesis (pp. 3–15). Cambridge University Press.

Vanyukov, M. M., Tarter, R. E., Kirillova, G. P., Kirisci, L., Reynolds, M. D., Kreek, M. J., Conway, K. P., Maher, B. S., Iacono, W. G., McGue, M., & Ridenour, T. A. (2012). Common liability to addiction and “gateway hypothesis”: Theoretical, empirical, and evolutionary perspective. Drug and Alcohol Dependence, 123(Suppl 1), S3–S17. 

Degenhardt, L., Dierker, L., Chiu, W. T., Medina-Mora, M. E., Neumark, Y., Sampson, N., Alonso, J., Angermeyer, M., Anthony, J. C., Bruffaerts, R., de Girolamo, G., de Graaf, R., Gureje, O., Karam, A. N., Kostyuchenko, S., Lee, S., Lépine, J. P., Levinson, D., Nakamura, Y., … Kessler, R. C. (2010). Evaluating the drug use “gateway” theory using cross-national data: Consistency and associations of the order of initiation of drug use among participants in the WHO World Mental Health Surveys. Drug and Alcohol Dependence, 108(1–2), 84–97. 

National Institute on Drug Abuse. (2020). Common comorbidities with substance use disorders research report. 

Volkow, N. D., & Boyle, M. (2018). Neuroscience of addiction: Relevance to prevention and treatment. American Journal of Psychiatry, 175(8), 729–740. 

Griffin, K. W., & Botvin, G. J. (2010). Evidence-based interventions for preventing substance use disorders in adolescents. Child and Adolescent Psychiatric Clinics of North America, 19(3), 505–526. 

United Nations Office on Drugs and Crime. (2018). World drug report 2018. United Nations. https://www.unodc.org